{
  "docId": "019de076-4f8b-70c9-adf8-0b3abb8c1303",
  "docSlug": "1af2d4156bf2490b3ac2801b5487abdf",
  "documentTitle": "Larimar Therapeutics | Investor Presentation Deck | 44 slides",
  "authorId": "larimar-therapeutics",
  "authorName": "Larimar Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 44,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "appendix_methodology",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The slide outlines the clinical trial methodology for a drug candidate in Friedreich's Ataxia (FA) patients.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4f8b-70c9-adf8-0b3abb8c1303/25",
  "deckHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303",
  "deckJsonHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303.json",
  "deckAnchorHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.036,
        "y": 0.4
      },
      "kind": "diagram",
      "text": "Single Ascending Dose (SAD) to Multiple Ascending Dose (MAD)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bedcbab2-29df-4252-a18c-bbb598fdceb6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.36,
        "y": 0.68
      },
      "kind": "list",
      "text": "Number of Subjects: 27\nDose Range: 25 mg, 50 mg, 100 mg (subcutaneous administration)\nTreatment Regimen: Multiple increasing doses administered subcutaneously over 13 days\n1º Endpoint: Safety and tolerability\n2º Endpoints: PK; PD; FXN levels (buccal cells, platelets, optional skin biopsies); multiple exploratory\nStatus: Complete",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "631a425d-0be2-4258-a878-aa1df97ed012",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.36,
        "y": 0.4
      },
      "kind": "list",
      "text": "Number of subjects: 28\nDose levels: 25 mg, 50 mg, 75 mg and 100 mg (subcutaneous administration)\nTreatment Duration: 1 day\n1º Endpoint: Safety and tolerability\n2º Endpoints: PK; PD; FXN levels; multiple exploratory\nStatus: Complete",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88ac0ce3-021d-40d8-a210-c1c407a3bf77",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.73,
        "x": 0.036,
        "y": 0.215
      },
      "kind": "list",
      "text": "Phase 1 Development Plan\nTwo double-blind, placebo-controlled dosing trials in patients with FA\nPatient dosing began December 2019\nSafety Review Committee assessed all blinded data between each cohort to ensure patient safety",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd4a3625-4150-4e2a-bf42-84abf24a3888",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.895,
        "x": 0.036,
        "y": 0.155
      },
      "kind": "paragraph",
      "text": "Program consisted of double-blind, placebo controlled single- and multiple-ascending dose trials",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31f24c4f-07dc-46d5-b616-103371db99f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.895,
        "x": 0.036,
        "y": 0.075
      },
      "kind": "title",
      "text": "CTI-1601: Phase 1 Clinical Program in Patients with FA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1920dcfd-faec-4851-bd60-c73bead3eb58",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 44,
      "from": 4,
      "beatId": "800ed350-717e-4cf5-a054-3d6626879633",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Multiple pages showcase clinical trial progress and data",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}